Gujarat Kidney appoints Dr Disha Bharpoda as independent director

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights

Appointed Mrs Disha Bharpoda as additional non-executive independent director. Term is five years starting August 24, 2026, subject to AGM approval. Mrs Bharpoda has an MD in Radiology and runs her own centre. Board noted shareholder approval for IPO proceeds utilisation variation.

powered bylight_fuzz_icon
49125737

*this image is generated using AI for illustrative purposes only.

Gujarat Kidney and Super Speciality appointed Mrs Disha Bharpoda as an additional non-executive independent director on August 24, 2026. The appointment follows a recommendation from the Nomination and Remuneration Committee and is subject to shareholder approval at the next annual general meeting.

The Board of Directors approved the appointment during its meeting held on August 24, 2026. Mrs Bharpoda will serve a first term of five consecutive years. She is not liable to retire by rotation.

Director Profile

Mrs Bharpoda holds an MD in Radiology from Baroda Medical College, Maharaja Sayajirao University, Vadodara, completed in 2021. Her professional background includes five years as a senior resident doctor. She subsequently established her own radiology centre.

The filing confirms that Mrs Bharpoda has no relationship with any existing director of the company.

Other Board Approvals

The board also took note of the approval given by shareholders via postal ballot for a special resolution. This resolution concerns the variation in the objects or terms of utilisation of the initial public offering proceeds.

The meeting commenced at 4:30 pm and concluded at 5 pm. Pragnesh Bharpoda, managing director, signed the disclosure filed with the BSE and NSE.

Historical Stock Returns for Gujarat Kidney and Super Speciality

1 Day5 Days1 Month6 Months1 Year5 Years
-0.28%+11.81%+17.46%+36.35%+45.92%+45.92%

How might Mrs. Bharpoda's specialized background in radiology influence Gujarat Kidney and Super Speciality's strategic expansion into diagnostic imaging services?

What specific changes to the IPO proceeds utilization are implied by the approved special resolution, and how will this reallocation impact the company's near-term capital expenditure?

Could the appointment of an independent director with a medical background signal a shift in corporate governance priorities towards clinical quality assurance or patient care standards?

Gujarat Kidney and Super Speciality
View Company Insights
View All News
like20
dislike

Gujarat Kidney shareholders approve variation in IPO proceeds utilisation

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights

Shareholders approved variation in IPO proceeds utilisation via postal ballot. Resolution passed with 99.99% support from 57 participating members. Promoter group voted unanimously in favour with all 56.3 million shares. Voting concluded on August 22, 2026, under SEBI LODR regulations.

powered bylight_fuzz_icon
49110835

*this image is generated using AI for illustrative purposes only.

Gujarat Kidney and Super Speciality shareholders approved a special resolution to vary the objects and terms of utilisation of its initial public offering proceeds. The remote e-voting concluded on August 22, 2026, with the resolution passing by a near-unanimous margin.

The company informed the Bombay Stock Exchange and the National Stock Exchange that the voting process complied with Regulation 44(3) of the SEBI (LODR) Regulations, 2015. The scrutinizer, SPANJ & Associates, confirmed the results were declared on the same day as the voting closure.

Voting Breakdown

A total of 57 members participated in the remote e-voting process, casting votes on 56,902,667 shares. The promoters and promoter group, holding 56,333,900 shares, voted entirely in favour of the resolution.

Category Votes in Favour Votes Against % Support
Promoter Group 56,333,900 0 100.00%
Public Institutions 54,125 0 100.00%
Public Non-Institutions 512,864 1,778 99.65%
Total 56,900,889 1,778 99.99%

Only one member abstained from voting, representing a single share. No votes were declared invalid during the scrutiny process conducted by Ashish Doshi of SPANJ & Associates.

Process Details

The postal ballot notice was dispatched electronically on July 22, 2026, to members registered as of the cut-off date on July 17, 2026. The e-voting window remained open from July 24, 2026, until August 22, 2026. The company published advertisements regarding the ballot in Financial Express and Gujarat Mitra newspapers to ensure wide dissemination among stakeholders.

Historical Stock Returns for Gujarat Kidney and Super Speciality

1 Day5 Days1 Month6 Months1 Year5 Years
-0.28%+11.81%+17.46%+36.35%+45.92%+45.92%

What specific strategic initiatives or capital expenditures will the varied IPO proceeds be allocated to, and how does this shift align with the company's long-term growth roadmap?

How might the reallocation of IPO funds impact Gujarat Kidney and Super Speciality's projected revenue streams and profitability margins over the next fiscal year?

Given the near-unanimous support from promoters and public institutions, what signals does this send to potential minority shareholders regarding management's confidence in the new operational direction?

Gujarat Kidney and Super Speciality
View Company Insights
View All News
like17
dislike

More News on Gujarat Kidney and Super Speciality

1 Year Returns:+45.92%